Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.40 |
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24936178 | 0.92 | HCAR2 (0.45) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL17688929 | 0.92 | HCAR2 (0.49) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL22535481 | 0.89 | MKNK1 (0.49) | HCAR2HCAR3HPGDTSHRMKNK1 | |
| SCHEMBL22327725 | 0.88 | DAO (0.44) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL24759495 | 0.85 | HCAR2 (0.47) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL21450656 | 0.82 | CCNA2 (0.42) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL1667926 | 0.82 | HCAR2 (0.47) | HCAR2HCAR3CCNA2CDK2CCNA1 | |
| SCHEMBL15032892 | 0.76 | HTT (0.63) | HPGDMEN1KMT2A | |
| SCHEMBL22535529 | 0.74 | NPC1 (0.35) | HPGDTSHR | |
| Hydrochloric Acid SCHEMBL3502428 | 0.73 | HCAR2 (0.40) | HCAR2HCAR3CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2023-07-06 | — | — | US | disclosed |
| US-20220194924-A1 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-06-23 | — | — | US | disclosed |
| WO-2022002118-A1 | FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-20210198261-A1 | AURORA KINASE INHIBITORS AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2021-07-01 | — | — | US | disclosed |
| US-10800760-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10738033-B2 | Trk inhibition | NANTBIO, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9796713-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796713-B2 | Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-8569298-B2 | Pyridine compounds | ASTRAZENECA AB (SE) | 2013-10-29 | — | — | US | disclosed |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2011-07-07 | — | — | US | disclosed |
| US-7446195-B2 | High affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION (US) | 2008-11-04 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | HCAR2 3305/4885HCAR3 2479/4885CCNA2 355/4885 |
| US-20170129892-A1 | TRICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA6, CHRNA5 | HCAR2 135/4885HCAR3 165/4885CCNA2 3871/4885 |
| US-10800760-B2 | Trk inhibition | NTRK1, NTRK3, NTRK2 | HCAR2 1049/4885HCAR3 536/4885CCNA2 2859/4885 |
| US-10738033-B2 | Trk inhibition | NGF, NGFR, NTRK2 | HCAR2 854/4885HCAR3 773/4885CCNA2 1497/4885 |
| US-20230212142-A9 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | CDK1, CDK12, CDK13 | HCAR2 3507/4885HCAR3 4052/4885CCNA2 26/4885 |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | DCK, TK1, DTYMK | HCAR2 3823/4885HCAR3 2807/4885CCNA2 616/4885 |
| US-20210198261-A1 | AURORA KINASE INHIBITORS AND USES THEREOF | AURKA, AURKC, AURKB | HCAR2 4319/4885HCAR3 3876/4885CCNA2 384/4885 |
| US-20110166139-A1 | PYRIDINE COMPOUNDS | PTK2, PTK2B, PFKP | HCAR2 2995/4885HCAR3 2660/4885CCNA2 2087/4885 |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | HCAR2 3823/4885HCAR3 2807/4885CCNA2 616/4885 |
| US-20070043045-A1 | Novel high affinity thiophene-based and furan-based kinase ligands | CDKL2, CDK2, CDKL1 | HCAR2 3255/4885HCAR3 3937/4885CCNA2 40/4885 |
| US-20220194924-A1 | Substituted 5-Cyclopropyl-1H-pyrazole-3-yl-amine Derivatives as Selective CDK12/13 Inhibitors | CDK1, CDK12, CDK13 | HCAR2 3507/4885HCAR3 4052/4885CCNA2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.